Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare TechnologiesNSE:THYROCARE +3.26%87 5-Year Yield-on-Cost % is 3.82 as of Aug. 25, 2026, which is 12% below its 10-year median of 4.36. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹425.85 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 62.9% on this metric.
Thyrocare Technologies's yield on cost for the quarter that ended in Jun. 2026 was 3.82.
The historical rank and industry rank for Thyrocare Technologies's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:THYROCARE'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.79 Med: 4.36 Max: 11.7
Current: 3.82
During the past 13 years, Thyrocare Technologies's highest Yield on Cost was 11.70. The lowest was 0.79. And the median was 4.36.
NSE:THYROCARE's 5-Year Yield-on-Cost % is ranked better than 62.9% of 62
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.39
vs NSE:THYROCARE: 3.82
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thyrocare Technologies 5-Year Yield-on-Cost % Related Terms
NSE:THYROCARE vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Thyrocare Technologies (NSE:THYROCARE) has a 5-Year Yield-on-Cost % of 3.82 as of Aug. 25, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Thyrocare Technologies and its competitors. This is 12% below median its historical median of 4.36. Over the past decade, Thyrocare Technologies' 5-Year Yield-on-Cost % has ranged from 0.79 to 11.70. According to the industry distribution chart, Thyrocare Technologies ranks #23 out of 62 companies in the Medical Diagnostics & Research industry, placing it in the top 37.1%.
Is Thyrocare Technologies' 5-Year Yield-on-Cost % too high?
Thyrocare Technologies' current 5-Year Yield-on-Cost % of 3.82 is 12% below median its 10-year median of 4.36. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 11.70. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.39. Thyrocare Technologies' value of 3.82 is 59.8% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #23 out of 62 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #23 out of 62 companies for 5-Year Yield-on-Cost %. This puts Thyrocare Technologies in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. Thyrocare Technologies' value of 3.82 is 59.8% above this benchmark. Historically, Thyrocare Technologies' own 5-Year Yield-on-Cost % has ranged from 0.79 to 11.70 over the past decade. While the company's 10-year median is 4.36 vs. the industry median of 2.39, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.39, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current 5-Year Yield-on-Cost % of 3.82 is 59.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current 5-Year Yield-on-Cost % is 3.82, which is 12% below median its own 10-year median of 4.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹425.85, compared to a current price of ₹584.00 — trading 37.1% above its estimated fair value. The current 5-Year Yield-on-Cost % is 3.82, which is 12% below median its 10-year median of 4.36 and 59.8% above the Medical Diagnostics & Research industry median of 2.39. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current 5-Year Yield-on-Cost % is 3.82 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹584.00 is trading 37.1% above its estimated GF Value™ of ₹425.85.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
5-Year Yield-on-Cost %: 3.82 (12% below median its 10-year median of 4.36)
GF Value™: ₹425.85 vs. price of ₹584.00 (37.1% above fair value)
Industry Position: 59.8% above the Medical Diagnostics & Research median (#23 of 62)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
